Topical therapies for glaucoma and ocular hypertension: An update on current practice
Eur J Ophthalmol 2003; 13 (Suppl. 4): S1 - S4
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 1 year
Eur J Ophthalmol 2003; 13 (Suppl. 4): S5 - S20
Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: Evidence from a European retrospective cohort study
Eur J Ophthalmol 2003; 13 (Suppl. 4): S21 - S29
Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France
Eur J Ophthalmol 2003; 13 (Suppl. 4): S30 - S43
Patient persistency with pharmacotherapy in the management of glaucoma
Eur J Ophthalmol 2003; 13 (Suppl. 4): S44 - S52
Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France
Eur J Ophthalmol 2003; 13 (Suppl. 4): S53 - S60